Fatigue after initiating rivaroxaban for venous thromboembolism.
anticoagulants
fatigue
pulmonary embolism
rivaroxaban
thrombosis
venous thromboembolism
venous thrombosis
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
18
06
2019
revised:
05
01
2020
accepted:
07
01
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has been observed in clinical practice, but data on this potential side effect are lacking. The study aimed to evaluate development of fatigue in patients treated for VTE, comparing rivaroxaban to other anticoagulants. Patients were prospectively recruited after a diagnosis of VTE. The Fatigue Questionnaire was used to determine the level of fatigue at baseline, at 3 weeks of treatment, and either at 1 month after the discontinuation of treatment if the treatment was discontinued after 3 months or at 6 months if treatment was continued beyond this time. Data was analyzed by a linear mixed model. A total of 126 patients were included. Mean age was 59 years; 77 (61%) were males. Fifty-seven patients (45%) were diagnosed with deep vein thrombosis, 48 (38%) with pulmonary embolism, and 21 (17%) with both. Predicted changes in fatigue scores from baseline to the last measurement were -0.007 and -2.49 for the rivaroxaban and the other-anticoagulants groups, respectively, neither of which were statistically significant. No difference was detected between rivaroxaban and the other-anticoagulants group at any time point, including subgroup analysis comparing over and under 6 months of treatment duration. In this small study, our results suggest no increase in the level of fatigue after the initiation of treatment with rivaroxaban for VTE.
Sections du résumé
BACKGROUND
BACKGROUND
Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has been observed in clinical practice, but data on this potential side effect are lacking.
OBJECTIVE
OBJECTIVE
The study aimed to evaluate development of fatigue in patients treated for VTE, comparing rivaroxaban to other anticoagulants.
METHODS
METHODS
Patients were prospectively recruited after a diagnosis of VTE. The Fatigue Questionnaire was used to determine the level of fatigue at baseline, at 3 weeks of treatment, and either at 1 month after the discontinuation of treatment if the treatment was discontinued after 3 months or at 6 months if treatment was continued beyond this time. Data was analyzed by a linear mixed model.
RESULTS
RESULTS
A total of 126 patients were included. Mean age was 59 years; 77 (61%) were males. Fifty-seven patients (45%) were diagnosed with deep vein thrombosis, 48 (38%) with pulmonary embolism, and 21 (17%) with both. Predicted changes in fatigue scores from baseline to the last measurement were -0.007 and -2.49 for the rivaroxaban and the other-anticoagulants groups, respectively, neither of which were statistically significant. No difference was detected between rivaroxaban and the other-anticoagulants group at any time point, including subgroup analysis comparing over and under 6 months of treatment duration.
CONCLUSION
CONCLUSIONS
In this small study, our results suggest no increase in the level of fatigue after the initiation of treatment with rivaroxaban for VTE.
Identifiants
pubmed: 32548556
doi: 10.1002/rth2.12312
pii: S2475-0379(22)01997-5
pmc: PMC7292653
doi:
Types de publication
Journal Article
Langues
eng
Pagination
582-585Informations de copyright
© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis.
Références
N Engl J Med. 2009 Dec 10;361(24):2342-52
pubmed: 19966341
J Psychosom Res. 1998 Jul;45(1):53-65
pubmed: 9720855
N Engl J Med. 2010 Dec 23;363(26):2499-510
pubmed: 21128814
N Engl J Med. 2013 Feb 21;368(8):699-708
pubmed: 23216615
Blood. 2010 Jan 7;115(1):15-20
pubmed: 19880491
Chest. 2012 Feb;141(2 Suppl):e419S-e496S
pubmed: 22315268
Scand J Gastroenterol. 2017 Mar;52(3):351-358
pubmed: 27852169
N Engl J Med. 2012 Apr 5;366(14):1287-97
pubmed: 22449293
Ann Pharmacother. 2005 May;39(5):840-2
pubmed: 15769830
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
N Engl J Med. 2013 Feb 21;368(8):709-18
pubmed: 23425163
BMJ. 2006 Jan 28;332(7535):215-9
pubmed: 16439400